Orchid Pharma Ltd
Orchid Pharma Ltd (ORCHPHARMA) last traded at ₹1,024, a market capitalisation of ₹6,134 crore, on a P/E of 340. Over the past 52 weeks the stock has ranged between ₹471 and ₹1,133. Orchid Pharma Ltd last reported results for the quarter ended Jun 2026, with sales of ₹304 crore and net profit of ₹3.22 crore. Figures are as of 25 Aug 2026 and are not real time.
Orchid Pharma Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Orchid Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹304 cr, up 15.6% from ₹263 cr a year earlier. Net profit turned positive at ₹3.22 cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 223 | 217 | 237 | 263 | 194 | 207 | 368 | 304 |
| Expenses | 192 | 191 | 209 | 269 | 195 | 206 | 338 | 290 |
| Operating profit | 30.34 | 26.37 | 27.99 | -5.65 | -1.47 | 1.56 | 30.16 | 14 |
| OPM % | 13.62% | 12.13% | 11.79% | -2.15% | -0.76% | 0.75% | 8.19% | 4.60% |
| Other income | 7.52 | 8.49 | 3.9 | 11.57 | 10.77 | -1.5 | 7.55 | 1.83 |
| Interest | 3.33 | 3.8 | 3.92 | 2.28 | 3.73 | 3.18 | 1.96 | 2.23 |
| Depreciation | 8.63 | 8.61 | 8.87 | 10.53 | 8.9 | 9.03 | 10.9 | 10.95 |
| Profit before tax | 25.9 | 22.45 | 19.1 | -6.89 | -3.33 | -12.15 | 24.85 | 2.65 |
| Tax % | 0.00% | 0.00% | -0.21% | 0.00% | 0.00% | 0.00% | 0.00% | 2.64% |
| Net profit | 27.24 | 20.78 | 22.29 | -5.69 | -5.72 | -12.61 | 25.84 | 3.22 |
| EPS (₹) | 5.37 | 4.10 | 4.39 | -1.12 | -1.13 | -2.49 | 5.09 | 0.63 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Orchid Pharma Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 450 | 560 | 666 | 819 | 922 | 1,233 | 1,073 |
| Operating profit | 29 | 55 | 84 | 111 | 118 | 34 | 44 |
| OPM % | 7% | 10% | 13% | 14% | 13% | 2.7% | 4.1% |
| Net profit | -117 | -2 | 46 | 92 | 100 | 10 | 11 |
| EPS (₹) | -28.55 | -0.48 | 11.35 | 18.17 | 19.65 | 1.96 | 2.10 |
TTM is the trailing twelve months to the most recent quarter.
Orchid Pharma Ltd growth and returns
- 10 Years
- 4%
- 5 Years
- 22%
- 3 Years
- 23%
- TTM
- 14%
- 10 Years
- 8%
- 5 Years
- 17%
- 3 Years
- 40%
- TTM
- -72%
- 10 Years
- 39%
- 5 Years
- 20%
- 3 Years
- 23%
- 1 Year
- 31%
- 10 Years
- %
- 5 Years
- 5%
- 3 Years
- 6%
- Last Year
- 1%
Orchid Pharma Ltd shareholding pattern
Promoters held 69.84% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.80% and DIIs 20.75%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% |
| FIIs | 1.94% | 2.53% | 2.69% | 1.39% | 1.56% | 1.17% | 0.87% | 0.80% |
| DIIs | 18.30% | 19.00% | 20.10% | 19.43% | 19.04% | 19.38% | 20.24% | 20.75% |
| Public | 9.94% | 8.63% | 7.37% | 9.34% | 9.57% | 9.61% | 9.04% | 8.62% |
| No. of shareholders | 36,363 | 34,158 | 34,303 | 39,827 | 38,155 | 35,709 | 35,118 | 33,433 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Orchid Pharma Ltd corporate filings
- Transcript of Analysts/Investors earning call held with public at large on August 21, 2026.Company Updatemedium impact
Cruxal's analysis: Orchid Pharma Limited reported Q1 FY27 revenue of INR 304 crore, reflecting 15% YoY…
Read the full analysis - Audio Recording of the Analyst/Investor Earning Call for Q-1 ended on June 30, 2026Company Updatelow impact
Cruxal's analysis: Orchid Pharma has filed the audio recording of its analyst/investor earnings call held…
Read the full analysis - Investors Presentation-Quarter 1 of F.Y.2026-27, ended on June 30, 2026.Company Updatehigh impact
Cruxal's analysis: Orchid Pharma Limited has released its Q1 FY27 investor presentation, highlighting a…
Read the full analysis - Intimation of schedule of Analysts/Investors Earning call for the Quarter-1 ended on June 30, 2026.Company Updatelow impact
Cruxal's analysis: Orchid Pharma Ltd has announced an investor and analyst earnings call to discuss the…
Read the full analysis - Statement of Deviation or variation for the quarter ended June 30, 2026 on the use of proceeds of Funds raised through Qualified Institutional Placement.Company Updatelow impact
Cruxal's analysis: Orchid Pharma has submitted its mandatory statement regarding the deviation or variation…
Read the full analysis - Monitoring Agency Report for Quarter-1 of F.Y. 2026-27 ended June 30, 2026.Company Updatelow impact
Cruxal's analysis: Orchid Pharma has submitted its Monitoring Agency Report for the first quarter of the…
Read the full analysis - Revised Audited financial results for the Financial year ended March 31, 2026 pursuant to Scheme of MergerCompany Updatelow impact
Cruxal's analysis: Orchid Pharma Limited has released revised standalone and consolidated financial results…
Read the full analysis - Financial Results for Quarter-1 of F.Y. 2026-27 ended on June 30, 2026.Resultmedium impact
Cruxal's analysis: Orchid Pharma Limited reported Q1 FY27 consolidated net sales of 304.17 crore and a net…
Read the full analysis - Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Unaudited Limited reviewed financial ....Board Meetinglow impact
Cruxal's analysis: Orchid Pharma Limited has announced a board meeting scheduled for August 14, 2026, to…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Orchid Pharma Ltd
Cruxal reads every Orchid Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.